CA-ESRI
17.12.2020 15:42:13 CET | Business Wire | Press release
Esri , the global leader in location intelligence, today announced that Newmont Corporation, a Colorado-based gold mining company, will use Site Scan for ArcGIS to supply drone workflow tools under its Global Drone Operating Model. With Site Scan for ArcGIS, Newmont will have a standardized, cloud-based platform to scale the company's drone operations, which span surface and underground facilities across seven countries. Newmont will use Site Scan for ArcGIS alongside ArcGIS Pro for monitoring and analysis, reclamation reporting, and improvement of health and safety initiatives.
Due to the frequently remote locations, monitoring mines and associated infrastructure by traditional methods can be time-consuming and costly, requiring an extensive workforce and posing a safety risk. Site Scan for ArcGIS enables improved decision-making and delivers value for Newmont in monitoring, surveying, and mapping these environments. Further, Site Scan for ArcGIS can be used to investigate topography and slope stability at Newmont's mine sites for improved safety as well as to audit mine inventory and area changes. Newmont has been using Site Scan for ArcGIS at its Boddington, Australia, site for several years, and in October 2020 the company initiated use of the solution at the Peñasquito Mine in Zacatecas, Mexico.
"Drones are an increasingly important enabler to safe and efficient operations," said Mike Wundenberg, vice president of Operating Technology and Business Improvement for Newmont. "Taking a common and consistent approach to how we apply them to capture quality data and then turn that into actionable insight makes a lot of business sense. Partnering with Esri to rapidly deploy Site Scan for ArcGIS across our operations and help further develop the system with our users is an exciting step on our digital journey."
Because Newmont has standardized procedures based on the use of Site Scan for ArcGIS under the Global Drone Operating Model, all drone operations at Newmont will generate the same high-quality 2D and 3D mapping and analytics products from the company's drone imagery. Newmont will also be able to publish and share this data to ArcGIS Online or ArcGIS Enterprise, making it available across the organization. Previously, operations were not standardized on any one drone management software solution, so the company did not always realize full value from its drone fleets and data.
"Site Scan for ArcGIS provides a best-in-class drone operations solution for customers at scale," said Richard Cooke, director of imagery and remote sensing at Esri. "We are honored and excited to be chosen by Newmont as its partner for implementing its Global Drone Operating Model. Esri's end-to-end solution will allow Newmont's operators to manage their drone fleet, facilitate decision-making across the mining life cycle, and drive efficiency in their operations."
To learn more about how organizations are using drone management to improve workflows, visit esri.com/en-us/arcgis/products/site-scan-for-arcgis/overview .
About Newmont
Newmont is the world's leading gold company and a producer of copper, silver, zinc and lead. The Company's world-class portfolio of assets, prospects and talent is anchored in favorable mining jurisdictions in North America, South America, Australia and Africa. Newmont is the only gold producer listed in the S&P 500 Index and is widely recognized for its principled environmental, social and governance practices. The Company is an industry leader in value creation, supported by robust safety standards, superior execution and technical expertise. Newmont was founded in 1921 and has been publicly traded since 1925.
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East. Esri has partners and local distributors in over 100 countries on six continents, including Fortune 500 companies, government agencies, nonprofits, and universities. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005693/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom